Clinical and Translational Epidemiology Branch (CTEB)
Andrew N. Freedman, Ph.D.
Branch Chief
The Clinical and Translational Epidemiology Branch (CTEB) focuses on etiologic and genomic factors that influence cancer progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions.
CTEB's mission is to plan, develop, direct, coordinate, and evaluate:
- A comprehensive program of epidemiologic research in human populations related to etiologic and genomic factors that influence cancer progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions;
- A program of epidemiologic research to study differences in cancer susceptibility and risk in individuals and populations and the multiple environmental and genetic factors that jointly contribute to development of cancer among individuals with underlying diseases and conditions and progression, recurrence, survival, and other treatment outcomes, and factors associated with cancer development among individuals with underlying diseases and conditions with the ultimate goal of elucidating cancer development and progression among people with these health conditions;
- A program of extramural epidemiologic research to evaluate the association of and magnitude of cancer risk associated with biomarkers of cancer development and progression in individuals with underlying diseases and cancer; and
- Resources, infrastructures, and consortia with a focus on cancer development and progression in individuals with underlying diseases and cancer to facilitate and maximize the scientific potential of cancer epidemiology research.
Its mission also is to disseminate findings from the research supported by the Branch to the public, health care professionals, scientists engaged in cancer control, and the public health community.
The populations studied in the grants in CTEB are primarily patient populations - individuals who have had cancer, have premalignant conditions or certain chronic or genetic diseases that may predispose to cancer, or have experienced certain treatments, such as immunosuppression after organ transplants, that may predispose to cancer.
CTEB Staff
| Branch | Name/Title | Contact Info | Interest Areas |
|---|---|---|---|
| CTEB | Freedman, Andrew N., Ph.D. Branch Chief |
301-435-6819 freedmaa@mail.nih.gov |
Developing, applying, and evaluating prediction models for cancer risk and prognosis; developing benefit/risk indices for pharmaceuticals used to prevent and treat cancer; and identifying clinical, epidemiologic, and pharmacogenomic factors related to cancer treatment outcomes |
| CTEB | Cook, Allison Extramural Support Specialist |
301-594-1744 cookal@mail.nih.gov |
Cancer and the Environment, Global Health, Risk Communication about Environmental Public Health, Long-term Effects of Exposure to Radiation and Toxins, Food Security, Urban Public Health Systems |
| CTEB | Filipski, Kelly K., Ph.D., M.P.H. Program Director |
301-435-4913 filipskikk@mail.nih.gov |
Pharmacogenomic factors related to cancer treatment outcomes and toxicity |
| CTEB | Ishibe Simonds, Naoko, Sc.D. Program Director |
301-594-1845 ishiben@mail.nih.gov |
Genetic and translational epidemiology, comparative effectiveness research, pharmacogenetics |
| CTEB | Shelburne, Nonniekaye F., C.R.N.P., M.S., A.O.C.N. Program Director |
301-594-6809 nshelburne@mail.nih.gov |
Benefit-risk prediction models for clinical oncology practice related to cancer treatment outcomes and toxicity |
| CTEB | Watters Elena, Joanne, Ph.D., M.P.H. Program Director |
301-451-9875 wattersj@mail.nih.gov |
Dietary and lifestyle risk factors related to cancer progression, recurrence, and survival outcomes |
| CTEB | Zhou, Yingjun (Grace), M.S. Cancer Research Training Award Fellow |
301-594-2256 grace.zhou@nih.gov |
Pharmacoepidemiology and drug safety, prediction models for cancer risks and treatment outcomes |
